ONC - BeiGene Short-Term Debt to Capital

Official company branding of beigene.com (ONC)

Risks for BeiGene Ltd (ONC) are linked to its ambitions of becoming a bridge between East and West in oncology. The dynamics of short-term loans under one year relative to equity serve as a stability indicator, where the 0.06 mark indicates the level of debt load. The situation is stabilized by the implementation of ESG standards in production and a temporary liquidity shortage resulting from large-scale clinical trials.

ONC - BeiGene Corp Current Liabilities to Capital over the range 07/04/2022 - 10/31/2026
Product sample of beigene.com

BeiGene Ltd (ONC) maintains a high dependence on external CRO contractors for clinical trials, which necessitates strict liquidity control. An analysis of the short-term leverage ratio allows for an assessment of the proportion of current liabilities relative to the company's equity. This metric measures the density of short-term borrowing, identifying the risk of cash flow gaps when servicing operating expenses. A stable trend confirms a balanced financial leverage, ensuring capital stability without excessive aggressive growth.

Analysis of competing companies

Short-Term Debt to Equity Halozyme Inc. (HALO)|Revolution Medicines Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital AAPG (Ascentage Pharma Group)|CGON - Short-Term Debt to Equity Ratio|UroGen Pharma - Short-Term Debt to Capital|Current Liabilities to Capital Bicara Therapeutics Inc|Personalis Corp (PSNL) - Short-Term Debt to Equity|Erasca Oncology - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio DCTH|YMAB: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AURA|Short-Term Debt to Equity Ratio candeltx.com CADL|Accuray Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital SELLAS Life Sciences Group, Inc. SLS|ACTU - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CTOR (citiusonc.com)|HURA: Short-Term Debt to Capital|Current Liabilities to Capital Protara Therapeutics Inc (TARA)|FATE (Fate Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Equity WHWK|Short-Term Debt to Capital TCRX|CSBR - Current Liabilities to Capital|Short-Term Debt to Capital XBIT (XBiotech)|Short-Term Debt to Capital Coefficient CEL-SCI Corp. (CVM)|OS Therapies Inc - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Radiopharm Theranostics Ltd (RADX)|ARTV: Short-Term Debt to Capital|Current Liabilities to Capital Adlai Nortye (ANL)|Short-Term Debt to Equity Veru|Short-Term Debt to Capital Ratio TPST (Tempest Therapeutics Inc)|Short-Term Debt to Capital XLO|RENB - Current Liabilities to Capital|Mural Oncology - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital KAPA|OKUR - Short-Term Debt to Equity|GDTC: Short-Term Debt to Equity|CRIS (curis.com) - Short-Term Debt to Equity Ratio|APLM: Short-Term Loans to Capital Ratio|THAR (Tharimmune, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio ADVB (Advanced Biomed Corp)|Short-Term Debt to Equity Genprex (GNPX)|CLDI - Current Liabilities to Capital|Short-Term Debt to Equity Sunshine Biopharma SBFM|XBIO: Short-Term Debt to Capital Ratio|Salarius Pharmaceuticals - Short-Term Debt to Capital|purple-biotech.com (PPBT) - Short-Term Debt to Equity Ratio|AONC: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio BeiGene Ltd.|CKPT (Checkpoint Therapeutics, Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Elevation Oncology Inc.|Short-Term Debt to Equity iCAD, Inc. (ICAD)|ikenaoncology.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital NTBL (Notable Labs)|VIRX - Short-Term Debt to Equity Ratio|MorphoSys Corp - Short-Term Debt to Capital|Current Liabilities to Capital NAYA Biosciences Corp|Ascentage Pharma Group (AAPGV) - Short-Term Debt to Equity